Windmill Cardiovascular Systems

Windmill Cardiovascular Systems

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Windmill Cardiovascular Systems is an innovative, clinical-stage medical device company pioneering a next-generation ventricular assist device (VAD) platform called TORVAD. Its unique two-piston, toroidal pump design aims to address key limitations of current continuous-flow VADs by providing synchronous, pulsatile support with significantly lower blood trauma. Led by a seasoned team with deep cardiovascular expertise, the company is advancing its platform for full, partial, and pediatric support indications, targeting a large and growing heart failure market. Windmill represents a high-potential, high-risk venture in the advanced heart failure therapy space.

CardiovascularHeart Failure

Technology Platform

TORVAD (Toroidal Ventricular Assist Device): A two-piston, positive displacement pump in a toroidal chamber that provides synchronous, pulsatile blood flow with low shear stress and integrated physiological sensing.

Opportunities

The TORVAD's gentle, pulsatile design could capture significant market share in the existing multi-billion dollar VAD market by offering a superior safety profile.
More disruptively, its partial-support 'mini' version could expand therapy to a much larger population of earlier-stage heart failure patients, creating a new market segment.

Risk Factors

Major risks include failure to demonstrate safety and efficacy in upcoming human clinical trials, the immense challenge of raising the $100M+ required for pivotal studies and commercialization, and competing against deeply entrenched incumbents like Abbott with the HeartMate 3.

Competitive Landscape

The durable LVAD market is a high-barrier duopoly dominated by Abbott's HeartMate 3. Windmill's primary competition is this established standard of care. Its differentiation is based on fundamental pump mechanics (pulsatile, low-shear vs. continuous-flow) aimed at reducing major adverse events, a key battleground in the field.